Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01747798 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer

Interventions

DRUG: auranofin
OTHER: laboratory biomarker analysis

Sponsor

Mayo Clinic